ArticleBMC cancer2021
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Intraperitoneal chemotherapy for gastric cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis.International journal of surgery (London, England) · 2023Pooled it
- Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials.Annals of surgical oncology · 2023Trial
- Safety and feasibility of total neoadjuvant FLOT chemotherapy in locally-advanced gastric and gastroesophageal junction cancer.Oncology letters · 2026Article
- XGBoost-based model for predicting five-year survival in gastric cancer using clinical indicators.Scientific reports · 2026Article
- Article
- Advances and challenges in the application of prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer.Frontiers in oncology · 2026Review
- Current Challenges and Future Directions in the Multimodal Management of Gastric Cancer with Peritoneal Metastases.Cancers · 2025Article
- Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy's role and outcomes.World journal of clinical oncology · 2025Article
- Therapeutic strategy for scirrhous type gastric cancer.Japanese journal of clinical oncology · 2025Review
- The Role of Prophylactic HIPEC in High-Risk Gastric Cancer Patients: Where Do We Stand?Cancers · 2025Review
- Tumor-Stroma Ratio is a Critical Indicator of Peritoneal Metastasis in Gastric Cancer.Clinical and experimental gastroenterology · 2025Article
- [Hand-foot syndrome after taking fibroblast growth factor receptor 2 inhibitor].Dermatologie (Heidelberg, Germany) · 2024Article
- Treatment of gastric cancer peritoneal metastases: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.The British journal of surgery · 2024Article
- International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Review
- Students and physicians differ in perception of quality of life in patients with tumors of the upper gastrointestinal tract.Scientific reports · 2024Article
- Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations.Current oncology (Toronto, Ont.) · 2024Review
- Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: Consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological Surgery.Annals of gastroenterological surgery · 2023Review
- Impact of positive microscopic resection margins (R1) after gastrectomy in diffuse-type gastric cancer.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 3 countries.
Funding
Abstract
backgroundThe main reason for treatment failure after curative surgical resection of gastric cancer is intra-abdominal spread, with 40-50% peritoneal seeding as primary localization of recurrence. Peritoneal relapse is seen in 60-70% of tumors of diffuse type, compared to only 20-30% of intestinal type. Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) is an increasingly used therapy method for patients with peritoneal metastases. The preventive use of HIPEC could represent an elegant approach for patients (pts) before macroscopic peritoneal seeding, since pts. with operable disease are fit and may have potential risk of microscopic involvement, thus having a theoretical chance of cure with HIPEC even without the need for cytoreduction. No results from a PCRT from the Western hemisphere have yet been published.
methodsThis is a multicenter, randomized, controlled, open-label study including a total of 200 pts. with localized and locally advanced diffuse or mixed type (Laurens's classification) adenocarcinoma of the stomach and Type II/III GEJ. All enrolled pts. will have received 3-6 pre-operative cycles of biweekly FLOT (Docetaxel 50 mg/m DISCUSSION: If the PREVENT concept proves to be effective, this could potentially lead to a new standard of therapy. On the contrary, if the outcome is negative, pts. with gastric cancer and no peritoneal involvement will not be treated with HIPEC during surgery.
trial registrationThe study is registered on June 25th, 2020 under ClinicalTrials.gov Identifier: NCT04447352 ; EudraCT: 2017-003832-35 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.